Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVST to prevent post-transplant viral infections
NCT02231853Phase 1Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2014
- Primary completion
- Nov 2017
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLA-matched multivirus-specific T cells in cytomegalovirus infection (CMV), Epstein-Barr virus infection, adenovirus infection and 1 more, sponsored by National Heart, Lung, and Blood Institute. Started Sep 2014; status: terminated.
02
Drugs
HLA-matched multivirus-specific T cells
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infectionBK virus infection
Beyond the preview
Go deeper on NCT02231853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231853.